Health Canada has conditionally approved the drug lecanemab to slow early-stage Alzheimer’s disease, raising questions about its effectiveness and availability in Canada.
Lecanemab is a lab-made antibody given by intravenous infusion. It targets the buildup of amyloid plaque in the brain, a hallmark of Alzheimer’s disease.
To read more, click on the link below:
https://www.cbc.ca/news/health/alzheimer-lecanemab-canada-9.6957634